Murat Soner ÇİRKİNOĞLU, Selcan DEMİR, Seza ÖZEN, Yelda BİLGİNER

Çocuklarda Behçet hastalığı: tek merkez deneyimi

Amaç: Bu çalışmada Behçet hastalığı tanısı almış çocuk hastaların demografik, klinik ve laboratuvar bulgularının özetlenmesi, uygulanan tedavilerin etkinliği, etki süreleri ve karşılaşılan yan etkilerin belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Hacettepe Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Nefroloji ve Romatoloji Bilim Dalları’nda 1980–2013 yılları arasında Uluslararası Behçet Çalışma Grubu ölçütlerine göre tanı almış 34 hastanın arşiv dosyaları ve elektronik kayıtları geriye dönük olarak incelenerek tüm demografik ve klinik özellikleri kaydedildi. Bu veriler ışığında çocukluk çağı Behçet olgularının cinsiyet ve yaş dağılımı, klinik ve laboratuvar bulguları, en çok tercih edilen tedavi yaklaşımları, tedavilerin etkinliği ve tedavi sırasında karşılaşılan yan etkiler incelendi. Bulgular: Otuz dört çocuk Behçet hastasının 18’i (%53) erkek ve 16’sı (%47) kızdı ve yaş ortalaması 11,18±3,34’tü. Kız ve erkek hastaların yaşlarının dağılımında anlamlı fark yoktu (p

Behçet’s disease in children: single-center experience

Aim: In this study, it was aimed to summarize the demographics, and clinical and laboratory findings of children who were diagnosed as having Behçet’s disease, and also to determine the efficacy, duration, and adverse effects of the treatments. Material and Methods: The records of 34 patients who were diagnosed according to the International Behçet Study Group criteria between 1980 and 2013 in the Department of Pediatric Nephrology and Rheumatology, Hacettepe University Faculty of Medicine, were retrospectively reviewed and all demographic and clinical features were recorded. In the light of these data, the sex and age distribution, clinical and laboratory findings, most commonly preferred treatment approaches, efficacy of treatments, and adverse effects during treatment were analyzed. Results: Of the 34 children with Behçet’s disease, 18 (53%) were male and 16 (47%) were female, and the mean age was 11.18±3.34 years. There was no significant difference in age distribution of the male and female patients (p

PDF

___

1. Behçet H. Über rezidiverende Aphthöse, durch ein Virus verusachte Geschwüre am Mund, am Auge und an den Genitalien.[Article in German] Dermatol Wochenschr 1937; 105: 1151−7.
2. Adamantiades B. Le thrombophlebite comme quatrieme symptom de I’iritis recidivante a hypopyon. Ann Ocul 1946; 179: 143-8.
3. Kone-Paut I, Shahram F, Darce-Bello M, et al; PEDBD group. Consensus classification criteria for paediatric Behcet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis 2016; 75: 958−64. [CrossRef]
4. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990; 335: 1078−80.
5. Evaluation of diagnostic (‘classification’) criteria in Behcet’s disease--towards internationally agreed criteria. International Study Group for Behcet’s disease. Br J Rheumatol 1992; 31: 299−308. [CrossRef]
6. Ozen S, Acar-Ozen NP. Recent advances in childhood vasculitis. Curr Opin Rheumatol 2017; 29: 530−4. [CrossRef]
7. Zayed HS, Medhat BM, Seif EM. Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life. Clin Rheumatol 2019; 38: 761−8. [CrossRef]
8. Karincaoglu Y, Borlu M, Toker SC, et al. Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol 2008; 58: 579−84. [CrossRef]
9. Koné-Paut I, Yurdakul S, Bahabri SA, et al. Epidemiological features of Behçet’s syndrome in children: an international collaborative survey of 86 cases. J Pediatr 1998; 132: 721−5. [CrossRef]
10. Kilian NC, Sawalha AH. Behcet’s disease in the United States: A single center descriptive and comparative study. Eur J Rheumatol 2017; 4: 239−44. [CrossRef]
11. Kim DK, Chang SN, Bang D, et al. Clinical analysis of 40 cases of childhood-onset Behçet’s disease. Pediatr Dermatol 1994; 11: 95−101. [CrossRef]
12. Gallizzi R, Pidone C, Cantarini L, et al. A national cohort study on pediatric Behçet’s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J 2017; 15: 84. [CrossRef]
13. Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 2016; 43: 620−32. [CrossRef]
14. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease. Semin Arthritis Rheum 1998; 27: 197−217. [CrossRef]
15. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2017: Behçet’s syndrome. Clin Exp Rheumatol 2017; 108: 3−15.
16. Sano K, Yakubi K, Imagawa Y, et al. The absence of disease-specific polymorphisms within the HLA B51 gene that is the susceptible locus for Behçet’s disease. Tissue antigens 2001; 58: 77−82. [CrossRef]
17. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term the rapy with low dose cyclosporin A in ocular Behcet’s disease. Doc Ophthalmol 2002; 105: 301−12. [CrossRef]
18. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 1990; 322: 281−5. [CrossRef]
19. Albayrak O, Oray M, Can F, et al. Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis. Invest Ophthalmol Vis Sci 2019; 60: 52−63. [CrossRef]
20. Yazıcı H, Yurdakul S, Hamuryudan V. Behçet’s syndrome. Curr Opin Rheumatol 2001; 13: 18−22.
21. Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol 2002; 16: 411−25. [CrossRef]
22. Hatemi G, Silman AD. Bang, et al; EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656−62.